Grant: Alliance Grants
Université de Montréal
$43,478.00
Continuous flow manufacturing process of 1,4-dithiothreitol to meet its increasing demand for disease test kits.
EF 2021-22
Résumé
The partnership between BioVectra Inc. and Prof. André B. Charette-Université de Montréal is a milestone towards an in-house Canadian manufacturing of high quality compounds in order to meet an increasing Canadian market demand. This approach will allow to mitigate Canada's heavy reliance on foreign suppliers and hence empower the Canadian economy and health care system. Specifically, the goal of this partnership is to develop an efficient synthetic route under continuous flow conditions to manufacture and supply on demand 1,4-dithiothreitol (DTT) to meet the rapidly expanding needs of the global and Canadian market. This reagent is routinely used as a key component in assays and in particular in COVID-19 testing kits where the demand has increased exponentially in the last year. The optimal synthetic procedure using continuous flow techniques will be develop within the Center for Continuous Flow Synthesis (CCFS), a state of the art laboratory located at Université de Montréal. The optimized process will then be effectively transfer to BioVectra's continuous flow large scale manufacturing facility for mass production and market distribution of DTT. This partnership is a turn-key solution to rapidly, safely and effectively supply the Canadian market with the crucially needed DTT. Through this partnership, trainees will gain experience in solving real world problems and well thought after pluri-disciplinary knowledge that will promote their successful entrance in the work force.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
562465-2021
Name nom
Charette, André
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
43478
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Installment
inst:1
Partie
1
Nb partie
1
Application title
Continuous flow manufacturing process of 1,4-dithiothreitol to meet its increasing demand for disease test kits.
Keyword
NSERC
Application summary
The partnership between BioVectra Inc. and Prof. André B. Charette-Université de Montréal is a milestone towards an in-house Canadian manufacturing of high quality compounds in order to meet an increasing Canadian market demand. This approach will allow to mitigate Canada's heavy reliance on foreign suppliers and hence empower the Canadian economy and health care system. Specifically, the goal of this partnership is to develop an efficient synthetic route under continuous flow conditions to manufacture and supply on demand 1,4-dithiothreitol (DTT) to meet the rapidly expanding needs of the global and Canadian market. This reagent is routinely used as a key component in assays and in particular in COVID-19 testing kits where the demand has increased exponentially in the last year. The optimal synthetic procedure using continuous flow techniques will be develop within the Center for Continuous Flow Synthesis (CCFS), a state of the art laboratory located at Université de Montréal. The optimized process will then be effectively transfer to BioVectra's continuous flow large scale manufacturing facility for mass production and market distribution of DTT. This partnership is a turn-key solution to rapidly, safely and effectively supply the Canadian market with the crucially needed DTT. Through this partnership, trainees will gain experience in solving real world problems and well thought after pluri-disciplinary knowledge that will promote their successful entrance in the work force.